Increased Cellular Death [PE] - N0000009176
Pharmacologic Class Information
Pharmacologic Code | N0000009176 |
Pharmacologic Name | Increased Cellular Death |
Pharmacologic Uses |
|
Pharmacologic Concept | Physiologic Effects - [PE] |
Pharmacologic Concept Description | This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept. |
NDC Products with Increased Cellular Death
The table contains 4 products whose active ingredient are classified under the same pharmacologic class Increased Cellular Death [PE].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0008-0100 | Besponsa | Non-Proprietary Name: Inotuzumab Ozogamicin | Injection, Powder, Lyophilized, For Solution | Intravenous | Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. | ACTIVE | |
0074-0561 | Venclexta | Non-Proprietary Name: Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | ACTIVE | |
0074-0566 | Venclexta | Non-Proprietary Name: Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | ACTIVE | |
0074-0576 | Venclexta | Non-Proprietary Name: Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | ACTIVE |